Zeng Xin, Sun Yu, Yang Hui-xia, Li Dong, Li Yu-xia, Liao Qin-ping, Wang Yan-ling
State Key Laboratory of Reproductive Biology, Institute of Zoology, Graduate School, Chinese Academy of Sciences, and Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China.
Am J Obstet Gynecol. 2009 Dec;201(6):618.e1-7. doi: 10.1016/j.ajog.2009.07.032. Epub 2009 Sep 20.
The objective of the study was to examine the relevance of the soluble form c-Met (sMet) with the clinical risk for severe preeclampsia.
This prospective case-control study was performed by using plasma derived from 44 preeclamptic and 51 uncomplicated pregnant women. Plasma concentration of sMet was measured with specific enzyme-linked immunosorbent assay, and the predictive values were determined based on the receiver-operating characteristic (ROC) curves analysis.
Plasma s-Met level in normal pregnant women changed in a gestation-dependent manner, peaking at weeks 19-24. In women with severe preeclampsia, the circulating sMet level was significantly lower than that in the gestational stage-matched controls during gestational weeks 15-30. The ROC curve analysis revealed a significant correlation between plasma sMet level and the risk of developing severe preeclampsia.
Plasma sMet could serve as a potential biomarker for predicting severe preeclampia at early second trimester of pregnancy.
本研究的目的是探讨可溶性c-Met（sMet）与重度子痫前期临床风险的相关性。
本前瞻性病例对照研究使用了44例子痫前期孕妇和51例正常孕妇的血浆。采用特异性酶联免疫吸附测定法测量sMet的血浆浓度，并基于受试者操作特征（ROC）曲线分析确定预测值。
正常孕妇血浆s-Met水平随孕周增加而变化，在孕19-24周达到峰值。在重度子痫前期孕妇中，孕15-30周期间循环sMet水平显著低于孕周匹配的对照组。ROC曲线分析显示血浆sMet水平与发生重度子痫前期的风险之间存在显著相关性。
血浆sMet可作为孕中期早期预测重度子痫前期的潜在生物标志物。
